Clinical Trial

Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer

Study acronym: PRELUCA
Recruiting
View on ClinicalTrials.gov →
Summary
The study is a prospective randomized interventional study including patients with advanced non-small cell lung cancer, receiving immunotherapy, with the aim of optimizing treatment monitoring. The study aims to investigate the clinical utility of liquid biopsy monitoring in order to reduce the numbers of inefficient treatments and needless toxicity - and to explore the cost-effectiveness and cost-utility of introducing liquid biopsy monitoring in daily clinical practice.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-25; most recent amendment 2026-01-06.
Status change: Not Yet Recruiting → Recruiting 2023-07-31
Trial Details
NCT Number NCT05889247
Lead Sponsor Zealand University Hospital
Conditions Non-small Cell Lung Cancer Metastatic
Enrollment 350 participants
Start Date 2023-07-28
Primary Completion 2027-06 (estimated)
Study Completion 2032-06 (estimated)
Updated on ClinicalTrials.gov 2026-01-09